Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in August 2009
*Drugs may be covered by multiple patents
| Tradename | Applicant | Generic Name | Patent Number | Patent Expiration |
| BREATHTEK UBT FOR H-PYLORI | Otsuka America | urea, c-13 | 5,140,993 | Aug 24, 2009 |
| COMBIVIR | Glaxosmithkline | lamivudine; zidovudine | 7,119,202 | Aug 8, 2009 |
| EPIVIR | Glaxosmithkline | lamivudine | 7,119,202 | Aug 8, 2009 |
| EPIVIR-HBV | Glaxosmithkline | lamivudine | 7,119,202 | Aug 8, 2009 |
| EPZICOM | Smithkline Beecham | abacavir sulfate; lamivudine | 7,119,202 | Aug 8, 2009 |
| EVOXAC | Daiichi Sankyo Co | cevimeline hydrochloride | 4,855,290 | Aug 30, 2009 |
| EXTRANEAL | Baxter Hlthcare | icodextrin | 4,761,237 | Aug 9, 2009 |
| LOVAZA | Smithkline Beecham | omega-3-acid ethyl esters | 5,698,594 | Aug 4, 2009 |
| MERETEK UBT KIT (W/ PRANACTIN) | Otsuka America | urea, c-13 | 5,140,993 | Aug 24, 2009 |
| RESTASIS | Allergan | cyclosporine | 4,839,342 | Aug 2, 2009 |
| TRIZIVIR | Glaxosmithkline | abacavir sulfate; lamivudine; zidovudine | 7,119,202 | Aug 8, 2009 |
| VFEND | Pfizer | voriconazole | 5,116,844 | Aug 11, 2009 |
Courtesy of DrugPatentWatch.com
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
![[Facebook]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/facebook.png)
![[Google]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/google.png)
![[LinkedIn]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Twitter]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/twitter.png)
![[Email]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/email.png)
{ 2 comments… read them below or add one }
GREETINGS
I AM REALLY LUCKY TO FIND THIS SITE . PATENTS TOPIC IS HIGHLY USEFUL IN MY JOB TO PICK DRUG APPLICATIONS WHERE THE PATENT REGULATIONS ARE NOT OBSEVED. THIS DESPITE THE TRIPS REGULATIONS WHICH ARE GLOBAL .
I THANK YOU FOR YOUR PRECIOUS HELP.YOU KNOW THAT IN THE FIELD OF DRUG REGISTRATION SHARING INTELLIGENCE AND HAVING THE RIGHT INFORMATION IS FUNDAMENTAL. AN APPLICATION WHERE THE IP REGULATIONS ARE NOT RESPECTED IS OBVIOUSLY NOT CONCERNED OF SAFETY QUALITY PURITY STABILITY OF THE API .
SINCERE THANKS & WARM REGARDS
MOHAMED FATHI SAFFAR Pharm.D
VICE-DIRECTOR AT THE NATIONAL LAB FOR DRUG CONTROL .TUNIS .TUNISIA
wonderful info,